Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL

Phase I oncology clinical trials often comprise a limited number of patients representing different disease subtypes who are divided into cohorts receiving treatment(s) at different dosing levels and schedules. Here, we leverage a previously developed quantitative systems pharmacology model of the a...

Descripción completa

Detalles Bibliográficos
Autores principales: Susilo, Monica E., Li, Chi‐Chung, Gadkar, Kapil, Hernandez, Genevive, Huw, Ling‐Yuh, Jin, Jin Y., Yin, Shen, Wei, Michael C., Ramanujan, Saroja, Hosseini, Iraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339700/
https://www.ncbi.nlm.nih.gov/pubmed/36908269
http://dx.doi.org/10.1111/cts.13501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339700/
https://www.ncbi.nlm.nih.gov/pubmed/36908269
http://dx.doi.org/10.1111/cts.13501

Ejemplares similares